Abstract
Micromet Inc, in collaboration with Merck Serono SA, is developing adecatumumab for the potential treatment of adenocarcinomas, including breast and prostate cancer. Adecatunmumab is a fully human antibody targeting epithelial cell adhesion molecule (EpCAM). Adecatumumab is currently undergoing phase II clinical trials in breast and prostate cancer.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal, Humanized
-
Antigens, Neoplasm / immunology*
-
Cell Adhesion Molecules / immunology*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Contraindications
-
Drug Evaluation, Preclinical*
-
Epithelial Cell Adhesion Molecule
-
Humans
-
Patents as Topic
-
Protein Engineering / methods*
-
Structure-Activity Relationship
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antigens, Neoplasm
-
Cell Adhesion Molecules
-
EPCAM protein, human
-
Epithelial Cell Adhesion Molecule
-
adecatumumab